oral+semaglutide+approval FDA approves first-ever oral GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only- oral-glp-1-for-weight-loss-in-adults The #FDA approved the first

Chipotle Mexican Grill launched a curated High Protein Menu with names centered around protein and fiber, with GLP-1 mentioned, but only in the fine print

Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta-analysis

Heart failure is a serious condition in which the heart struggles to pump enough blood

All doses of Novo Nordisks blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administrations drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs

Lead author Dr Ilaria Costantini (UCL Psychiatry) said: Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide

Semaglutide initiates appetite suppression through GLP-1 receptor activation in the brain within 24 to 48 hours of your first dose, though visible weight loss follows a more gradual pattern